Artivion reports second quarter 2023 financial results

Second quarter and recent business highlights: achieved revenue of $89.3 million in the second quarter of 2023 versus $80.3 million in the second quarter of 2022, an increase of 11% on both a gaap and non-gaap constant currency basis net loss was ($3.4) million or ($0.08) per share; non-gaap net income was $2.3 million or $0.06 per share achieved ebitda of $9.2 million in the second quarter of 2023; non-gaap adjusted ebitda increased 35% to $13.8 million in the second quarter of 2023 compared to the second quarter of 2022 aortic stent graft revenues increased 19% on both a gaap and non-gaap constant currency basis in the second quarter of 2023 compared to the second quarter of 2022 on-x revenues increased 10% on a gaap basis and 11% on a non-gaap constant currency basis in the second quarter of 2023 compared to the second quarter of 2022 received perclot pma approval and commenced shipping product to baxter patient enrollment in the persevere clinical trial accelerated with enrollment completion expected in the third quarter of 2023 atlanta , aug. 3, 2023 /prnewswire/ -- artivion, inc. (nyse: aort), a leading cardiac and vascular surgery company focused on aortic disease, today announced its financial results for the second quarter ended june 30, 2023. "our second quarter results reflect the strength of our business commercially, operationally, and financially.
AORT Ratings Summary
AORT Quant Ranking